Joel Greenblatt's ALNY Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 28.1K shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $12.83 M, representing 0.06% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in ALNY, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 11.2K shares. Largest reduction occurred in Q1 2024, reducing 8.8K shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2017 | +9,684 | New Buy | 9,684 | $79.72 |
| Q3 2017 | -7,185 | Reduce 74.19% | 2,499 | $117.65 |
| Q4 2017 | -2,499 | Sold Out | 2,499 | $0.00 |
| Q4 2019 | +2,920 | New Buy | 2,920 | $115.07 |
| Q1 2020 | +1,544 | Add 52.88% | 4,464 | $108.87 |
| Q2 2020 | -4,464 | Sold Out | 4,464 | $0.00 |
| Q1 2022 | +1,298 | New Buy | 1,298 | $163.33 |
| Q2 2022 | +1,808 | Add 139.29% | 3,106 | $145.85 |
| Q3 2022 | +277 | Add 8.92% | 3,383 | $200.12 |
| Q4 2022 | +3 | Add 0.09% | 3,386 | $237.65 |
| Q1 2023 | +1,730 | Add 51.09% | 5,116 | $200.32 |
| Q2 2023 | -1,259 | Reduce 24.61% | 3,857 | $189.94 |
| Q3 2023 | -775 | Reduce 20.09% | 3,082 | $177.10 |
| Q4 2023 | +7,727 | Add 250.71% | 10,809 | $191.41 |
| Q1 2024 | -8,762 | Reduce 81.06% | 2,047 | $149.45 |
| Q2 2024 | +11,190 | Add 546.65% | 13,237 | $243.00 |
| Q3 2024 | +4,338 | Add 32.77% | 17,575 | $275.03 |
| Q4 2024 | -6,651 | Reduce 37.84% | 10,924 | $235.31 |
| Q1 2025 | +3,593 | Add 32.89% | 14,517 | $270.02 |
| Q2 2025 | +3,270 | Add 22.53% | 17,787 | $326.09 |
| Q3 2025 | +10,348 | Add 58.18% | 28,135 | $456.00 |
Joel Greenblatt's Alnylam Pharmaceuticals Investment FAQs
Joel Greenblatt first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q2 2017, acquiring 9,684 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Alnylam Pharmaceuticals, Inc. (ALNY) for 34 quarters since Q2 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q2 2024, adding 13,237 shares worth $3.22 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 28,135 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $12.83 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.06% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 28,135 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.